title: Heterodimerization of dopamine receptors: new insights into functional and therapeutic significance.
abstract: G-protein-coupled receptors (GPCRs) exist both as monomers and also as dimers or higher-order oligomers, representing assemblies either with their peers or with other classes of GPCR ("heterodimers"). The pharmacological profiles of heterodimers often differ from the corresponding monomers or homodimers. Heterodimerization of dopamine receptors has been shown for both the D1/D5 and D2/D3/D4 receptor families, which couple positively and negatively, respectively, to adenylyl cyclase. Notably, heterodimers are formed by: D1 and adenosine A1 receptors; D2 or D3 and adenosine A2 receptors; and D2 and somatostatin SST5 receptors. Further, D1, D2 and D3 receptors physically assemble into functional D1/D2, D1/D3 and D2/D3 heterodimers possessing binding and coupling profiles distinct from the respective monomers. This article reviews data on dopamine D3/D2 and D3/D1 heterodimers, including observations that some antiparkinsonian agents--such as the preferential high-efficacy D3 versus D2 receptor agonists, pramipexole and ropinirole--show amplified potency at D3/D2 heterodimers versus constituent monomers, and others in contrast, such as the D3/D2 receptor agonist pergolide, show no difference. This article also discusses allosteric modulation amongst heterodimeric dopamine receptors, whereby agonist actions at one member of a heterodimer influence functional coupling at the other protomer. Finally, it presents data showing that, in cells co-transfected with D3 and D1 receptors, long-term exposure to pramipexole and ropinirole (which possess negligible affinities for D1 sites) elicits supersensitivity of D1 receptor-activated adenylyl cyclase, and conversely, D3/D2 receptor agonists such as apomorphine and bromocriptine (which also act as D1 receptor agonists) do not. A hypothetical relationship between these observations and the exacerbation of gambling in Parkinson's disease by antiparkinsonian agents is discussed.
authors.affiliation: Department of Experimental Medicine, University of L'Aquila, L'Aquila, Italy. roberto.maggio@univaq.it
authors.forename: Roberto
authors.initials: R
authors.lastname: Maggio
authors.forename: Gabriella
authors.initials: G
authors.lastname: Aloisi
authors.forename: Elena
authors.initials: E
authors.lastname: Silvano
authors.forename: Mario
authors.initials: M
authors.lastname: Rossi
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Millan
mesh_terms: D000818:Animals; D000978:Antiparkinson Agents / Q000378:metabolism; D018491:Dopamine Agonists / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism*; D055503:Protein Multimerization / Q000502:physiology*; D011954:Receptors, Dopamine / Q000378:metabolism / Q000502:physiology*
chemical_list: D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D011954:Receptors, Dopamine